{
    "eid": "2-s2.0-85100655698",
    "title": "Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial",
    "cover-date": "2021-02-13",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Medicine (all)",
            "@code": "2700",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Ahmet Sezer",
        "Saadettin Kilickap",
        "Mahmut G\u00fcm\u00fc\u015f",
        "Igor Bondarenko",
        "Mustafa \u00d6zg\u00fcro\u011flu",
        "Miranda Gogishvili",
        "Haci M. Turk",
        "Irfan Cicin",
        "Dmitry Bentsion",
        "Oleg Gladkov",
        "Philip Clingan",
        "Virote Sriuranpong",
        "Naiyer Rizvi",
        "Bo Gao",
        "Siyu Li",
        "Sue Lee",
        "Kristina McGuire",
        "Chieh I. Chen",
        "Tamta Makharadze",
        "Semra Paydas",
        "Marina Nechaeva",
        "Frank Seebach",
        "David M. Weinreich",
        "George D. Yancopoulos",
        "Giuseppe Gullo",
        "Israel Lowy",
        "Petra Rietschel"
    ],
    "citedby-count": 330,
    "ref-count": 30,
    "ref-list": [
        "Frontline immunotherapy for NSCLC: alone or not alone?",
        "Immunotherapy in treatment na\u00efve advanced non-small cell lung cancer",
        "Pembrolizumab versus chemotherapy for PD-L1\u2013positive non-small-cell lung cancer",
        "Pembrolizumab versus docetaxel for previously treated, PD\u2013L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial",
        "Pembrolizumab for the treatment of non-small-cell lung cancer",
        "Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC",
        "Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update",
        "NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Version 6",
        "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial",
        "Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes",
        "Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice",
        "Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice",
        "PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma",
        "Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial",
        "First-in-human study of cemiplimab alone or in combination with radiotherapy and/or low-dose cyclophosphamide in patients with advanced malignancies",
        "Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): interim data from a phase I dose escalation and NSCLC expansion cohort",
        "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)",
        "Interpreting the significance of changes in health-related quality-of-life scores",
        "PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project",
        "A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer",
        "Lung cancer in women, a different disease: survival differences by sex in Turkey",
        "A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer",
        "Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: a cross-trial comparison of two phase III trials",
        "Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater",
        "Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer",
        "Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial",
        "Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC",
        "Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing",
        "First-line nivolumab in stage IV or recurrent non-small-cell lung cancer",
        "Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial"
    ],
    "affiliation": [
        {
            "affiliation-city": "Wollongong",
            "@id": "60189138",
            "affilname": "Illawarra Health and Medical Research Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60189138",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Istanbul",
            "@id": "60104438",
            "affilname": "Istanbul Medeniyet University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60104438",
            "affiliation-country": "Turkey"
        },
        {
            "affiliation-city": "Istanbul",
            "@id": "60104413",
            "affilname": "Bezmi\u00e2lem Vak\u0131f \u00dcniversitesi",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60104413",
            "affiliation-country": "Turkey"
        },
        {
            "affiliation-city": "Dnipro",
            "@id": "60070090",
            "affilname": "Dnipro State Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60070090",
            "affiliation-country": "Ukraine"
        },
        {
            "affiliation-city": "Adana",
            "@id": "60032587",
            "affilname": "\u00c7ukurova \u00dcniversitesi",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032587",
            "affiliation-country": "Turkey"
        },
        {
            "affiliation-city": "Ankara",
            "@id": "60028644",
            "affilname": "Ba\u015fkent \u00dcniversitesi",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028644",
            "affiliation-country": "Turkey"
        },
        {
            "affiliation-city": "New York",
            "@id": "60027565",
            "affilname": "Columbia University Irving Medical Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60027565",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Tarrytown",
            "@id": "60023187",
            "affilname": "Regeneron Pharmaceuticals, Inc.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60023187",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Ankara",
            "@id": "60020484",
            "affilname": "Hacettepe \u00dcniversitesi",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020484",
            "affiliation-country": "Turkey"
        },
        {
            "affiliation-city": "Istanbul",
            "@id": "60010811",
            "affilname": "\u0130stanbul University-Cerrahpa\u015fa Cerrahpa\u015fa Faculty of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60010811",
            "affiliation-country": "Turkey"
        },
        {
            "affiliation-city": "Edirne",
            "@id": "60003941",
            "affilname": "Trakya \u00dcniversitesi",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60003941",
            "affiliation-country": "Turkey"
        },
        {
            "affiliation-city": "Sverdlovsk",
            "@id": "125759034",
            "affilname": "Sverdlovsk Regional Oncology Centre",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/125759034",
            "affiliation-country": "Russian Federation"
        },
        {
            "affiliation-city": "Batumi",
            "@id": "125759008",
            "affilname": "High Technology Hospital Medcenter",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/125759008",
            "affiliation-country": "Georgia"
        },
        {
            "affiliation-city": "Chelyabinsk",
            "@id": "123855653",
            "affilname": "LLC",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/123855653",
            "affiliation-country": "Russian Federation"
        },
        {
            "affiliation-city": "Basking Ridge",
            "@id": "113828800",
            "affilname": "Regeneron Pharmaceuticals, Inc.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/113828800",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Tbilisi",
            "@id": "109407418",
            "affilname": "University Clinic",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/109407418",
            "affiliation-country": "Georgia"
        },
        {
            "affiliation-city": "Arkhangelsk",
            "@id": "101095549",
            "affilname": "Arkhangelsk Clinical Oncology Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/101095549",
            "affiliation-country": "Russian Federation"
        }
    ],
    "funding": [
        "IDMC"
    ]
}